^
    over2years
    CDH6 as a prognostic indicator and marker for chemotherapy in gliomas. (PubMed, Front Genet)
    Potential drugs associated with high CDH6 expression were also predicted, including AMG-22, rutin, CCT128930, deforolimus, bis(maltolato)oxovanadium, anagrelide, vemurafenib, CHIR-98014, and AZD5582. Thus, this study showed that CDH6 correlates with glioma immune infiltration, it is expressed mainly in AC-like malignant cells, and it may act as a new target for glioma therapy.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    Zelboraf (vemurafenib) • CCT128930 • AZD5582 • Taltorvic (ridaforolimus)
    over4years
    CCT128930 induces G1-phase arrest and apoptosis and synergistically enhances the anticancer efficiency of VS5584 in human osteosarcoma cells. (PubMed, Biomed Pharmacother)
    Moreover, CCT128930 treatment obviously enhanced VS5584-induced growth inhibition and apoptosis in human osteosarcoma cells, followed by enhanced PARP cleavage and caspase-3 activation. Taken together, CCT128930 alone or combined treatment with CCT128930 and VS5584 both effectively inhibited human osteosarcoma cells growth by induction of G1-phase arrest and apoptosis through regulating PI3K/mTOR and MAPKs pathways.
    Journal • PARP Biomarker
    |
    CCND1 (Cyclin D1) • CASP3 (Caspase 3) • CDK1 (Cyclin-dependent kinase 1) • CCNB1 (Cyclin B1)
    |
    CCT128930 • VS-5584